Dapirolizumab Pegol - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Typhoon Bavi forces mass evacuations and widespread flight cancellations across Taiwan as authorities brace for extreme rainfall, flooding and landslide risks. Representative image.

Typhoon Bavi shuts Taiwan as 14,000 evacuate and more than 1,190 flights are cancelled

BHP explores a potential $2 billion sale of Chilean desalination and electricity transmission assets supporting its major copper operations. Representative image.

BHP (ASX: BHP) explores $1.5-$2bn sale of Chilean desalination plant and power lines

Vodafone shares surge after Xavier Niel’s Vega agrees to acquire e&’s 16.21 percent stake in a £4.4 billion transaction. Representative image.

Vodafone (LSE: VOD) jumps 12% as Xavier Niel’s Vega buys e&’s 16.21% stake for £4.4bn

GlobalWafers and Micron Technology expand United States semiconductor supply capacity through a $500 million financing and 10-year silicon wafer agreement. Representative image.

GlobalWafers locks in $500m Micron financing and 10-year Sherman wafer supply pact

Representative image: A clinical researcher reviews patient data in a modern medical laboratory, reflecting Biogen and UCB’s Phase 3 progress for dapirolizumab pegol in systemic lupus erythematosus treatment.

Read More

Pharma Industry News

Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?

Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.

byPallavi Madhiraju

June 1, 2026

web analytics